前列腺癌早期诊断标志物的研究进展

年新文; 任善成; 许传亮; 孙颖浩

doi:10.13201/j.issn.1001-1420.2016.09.021

前列腺癌早期诊断标志物的研究进展

- 第二军医大学长海医院泌尿外科(上海, 200433)

详细信息

通讯作者: 孙颖浩,E-mail:sunyhsmmu@126.com

中图分类号: R737.25

收稿日期: 2016-08-08

Research progress of markers in early diagnosis of prostate cancer

- Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China

More Information

Corresponding author: SUN Yinghao, E-mail: sunyhsmmu@126.com

Received Date: 08 August 2016

摘要

摘要: 前列腺癌是最常见的男性恶性肿瘤之一。近年来,前列腺癌在我国的发病率呈逐年上升趋势。前列腺癌的早期诊断对指导前列腺癌穿刺、治疗方式以及疾病预后具有直接的影响。目前,前列腺癌筛查的最常用标志物前列腺特异抗原并不是肿瘤特异性标志物,人们发现其用于前列腺癌早期诊断的特异性并不理想,导致了较多不必要的穿刺。因此,获取与前列腺癌高度相关性的肿瘤标志物是现今的研究热点。近年来新发现的长链非编码RNA、单核苷酸多态性及融合基因等分子已被证实与肿瘤具有相关性,可明显提高前列腺癌的诊断效能。本文现就前列腺特异抗原和新发现的几种相关肿瘤标志物在前列腺癌诊断方面的研究进展做一综述。
- 前列腺癌 /
- 早期诊断 /
- 分子标志物
Abstract: Prostate cancer(PCa)is one of the most common malignancies in males,and its incidence has increased year by year.The early diagnosis of PCa directly influences the choices of prostate biopsy,treatment and prognosis of the cancer.In fact,prostate specific antigen(PSA)regarded as a common marker in cancer screening isn't the specific tumor marker.Its specificity for tumor diagnosis isn't satisfactory,so that many unnecessary biopsies occur.Searching for highly specific tumor markers becomes a research hotspot.Nowadays long noncoding RNA(IncRNA),single nucleotide polymorphisms(SNPs),fusion gene and other molecular markers have been affirmed to be associated with PCa,so that the diagnostic level of PCa can be obviously improved.This article will focus on research progress of PSA and other new cancer-related markers in diagnosis of PCa.
- prostate cancer /
- early diagnosis /
- molecular markers

HTML全文

参考文献(45)

[1]	1.Siegel R L,Miller K D,Jemal A,et al.Cancer statistics,2016[J].CA Cancer J Clin,2016,66(1):7-30.
[2]	韩苏军,张思维,陈万青,等.中国前列腺癌发病现状和流行趋势分析[J].临床肿瘤学杂志,2013,18(4):330-334.
[3]	Lojanapiwat B,Anutrakulchai W,Chongruksut W,et al.Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis,aggressiveness,and bone metastasis of prostate cancer in clinical practice[J].Prostate Int,2014,2(3):133-139.
[4]	Hedelin H,Johansson N,Stroberg P.Relationship between benign prostatic hyperplasia and lower urinary tract symptoms and correlation between prostate volume and serum prostate-specific antigen in clinical routine[J].Scand J Urol Nephrol,2005,39(2):154-159.
[5]	Simardi L H,Tobias-MacHado M,Kappaz G T,et al.Influence of asymptomatic histologic prostatitis on serum prostate-specific antigen:aprospective study[J].Urology,2004,64(6):1098-1101.
[6]	Roehrborn C G,Pickens G J,Carmody T,3rd.Variability of repeated serum prostate-specific antigen(PSA)measurements within less than 90 days in a well-defined patient population[J].Urology,1996,47(1):59-66.
[7]	Lane B R,Zippe C D,Abouassaly R,et al.Saturation technique does not decrease cancer detection during followup after initial prostate biopsy[J].J Urol,2008,179(5):1746-1750.
[8]	Auvinen A,Maattanen L,Finne P,et al.Test sensitivity of prostate-specific antigen in the Finnish randomised prostate cancer screening trial[J].Int J Cancer,2004,111(6):940-943.
[9]	Vedder M M,de Bekker-Grob E W,Lilja H G,et al.The added value of percentage of free to total prostatespecific antigen,PCA3,and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men[J].Eur Urol,2014,66(6):1109-1115.
[10]	Parekh D J,Punnen S,Sjoberg D D,et al.A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer[J].Eur Urol,2015,68(3):464-470.
[11]	Stephan C,Schnorr D,Loening S A,et al.Use of prostate-specific antigen(PSA)isoforms for the detection of prostate cancer in men with a PSA Level of 2-10ng/ml:systematic review and meta-analysis[J].Eur Urol,2005,48(3):386-399.
[12]	Hori S,Blanchet J S,McLoughlin J.From prostatespecific antigen(PSA)to precursor PSA(proPSA)isoforms:a review of the emerging role of proPSAs in the detection and management of early prostate cancer[J].BJU Int,2013,112(6):717-728.
[13]	Guazzoni G,Nava L,Lazzeri M,et al.Prostate-specific antigen(PSA)isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0and 10ng/ml:results of a prospective study in a clinical setting.Eur Urol,2011,60(2):214-222.
[14]	Stephan C,Kahrs A M,Cammann H,et al.A[-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases[J].Prostate,2009,69(2):198-207.
[15]	Stephan C,Vincendeau S,Houlgatte A,et al.Multicenter evaluation of[-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer[J].Clin Chem,2013,59(1):306-314.
[16]	Chun F K,de la Taille A,van Poppel H,et al.Prostate cancer gene 3(PCA3):development and internal validation of a novel biopsy nomogram[J].Eur Urol,2009,56(4):659-667.
[17]	de la Taille A,Irani J,Graefen M,et al.Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions[J].J Urol,2011,185(6):2119-2125.
[18]	Hessels D,Schalken J A.The use of PCA3 in the diagnosis of prostate cancer[J].Nat Rev Urol,2009,6(5):255-261.
[19]	Chevli K K,Duff M,Walter P,et al.Urinary PCA3 as a predictor of prostate cancer in a cohort of 3,073men undergoing initial prostate biopsy[J].J Urol,2014,191(6):1743-1748.
[20]	Birnbaum J K,Feng Z,Gulati R,et al.Projecting Benefits and Harms of Novel Cancer Screening Biomarkers:A Study of PCA3 and Prostate Cancer[J].Cancer Epidemiol Biomarkers Prev,2015,24(4):677-682.
[21]	Ren S,Liu Y,Xu W,et al.Long noncoding RNAMALAT-1is a new potential therapeutic target for castration resistant prostate cancer[J].J Urol,2013,190(6):2278-2287.
[22]	Wang F,Ren S,Chen R,et al.Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1as a diagnostic urinary biomarker for prostate cancer[J].Oncotarget,2014,5(22):11091-11102.
[23]	Soller M J,Isaksson M,Elfving P,et al.Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer[J].Genes Chromosomes Cancer,2006,45(7):717-719.
[24]	Leyten G H,Hessels D,Jannink S A,et al.Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer[J].Eur Urol,2014,65(3):534-542.
[25]	Merdan S,Tomlins S A,Barnett C L,et al.Assessment of long-term outcomes associated with urinary prostate cancer antigen 3and TMPRSS2:ERG gene fusion at repeat biopsy[J].Cancer,2015,121(22):4071-4079.
[26]	Selvaraj N,Kedage V,Hollenhorst P C.Comparison of MAPK specificity across the ETS transcription factor family identifies a high-affinity ERK interaction required for ERG function in prostate cells[J].Cell Commun Signal,2015,13:12.
[27]	Ren S,Peng Z,Mao J H,et al.RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions,cancer-associated long noncoding RNAs and aberrant alternative splicing[J].Cell Res,2012,22(5):806-821.
[28]	Annenkov A,Nishikura K,Domori K,et al.Alphamethylacyl-coenzyme A racemase expression in neuroendocrine neoplasms of the stomach[J].Virchows Arch,2012,461(2):169-175.
[29]	Helal Tel A,Radwan N A,Abdel Kader Z,et al.Role of alpha methylacyl-coenzyme A racemase in differentiating hepatocellular carcinoma from dysplastic and nondysplastic liver cell lesions[J].Ann Diagn Pathol,2012,16(5):330-334.
[30]	Lakis S,Papamitsou T,Panagiotopoulou C,et al.AMACR is associated with advanced pathologic risk factors in sporadic colorectal adenomas[J].World JGastroenterol,2010,16(20):2476-2483.
[31]	Carter H B,Isaacs W B.Improved biomarkers for prostate cancer:a definite need[J].J Natl Cancer Inst,2004,96(11):813-815.
[32]	Sreekumar A,Laxman B,Rhodes D R,et al.Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer[J].J Natl Cancer Inst,2004,96(11):834-843.
[33]	Bradley S V,Oravecz-Wilson K I,Bougeard G,et al.Serum antibodies to huntingtin interacting protein-1:a new blood test for prostate cancer[J].Cancer Res,2005,65(10):4126-4133.
[34]	Liu F,Hsing A W,Wang X,et al.Systematic confirmation study of reported prostate cancer risk-associated single nucleotide polymorphisms in Chinese men[J].Cancer Sci,2011,102(10):1916-1920.
[35]	Chan J Y,Li H,Singh O,et al.8q24 and 17q prostate cancer susceptibility loci in a multiethnic Asian cohort[J].Urol Oncol,2013,31(8):1553-1560.
[36]	Zheng S L,Sun J,Wiklund F,et al.Cumulative association of five genetic variants with prostate cancer[J].N Engl J Med,2008,358(9):910-919.
[37]	Carthew R W,Sontheimer E J.Origins and Mechanisms of miRNAs and siRNAs[J].Cell,2009,136(4):642-655.
[38]	Shi X B,Xue L,Ma A H,et al.miR-125bpromotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes[J].Prostate,2011,71(5):538-549.
[39]	Watahiki A,Wang Y,Morris J,et al.MicroRNAs associated with metastatic prostate cancer.PloS one,2011,6(9):e24950.
[40]	Ribas J,Ni X,Haffner M,et al.miR-21:an androgen receptor-regulated microRNA that promotes hormonedependent and hormone-independent prostate cancer growth[J].Cancer Res,2009,69(18):7165-7169.
[41]	Brase J C,Johannes M,Schlomm T,et al.Circulating miRNAs are correlated with tumor progression in prostate cancer[J].Int J Cancer,2011,128(3):608-616.
[42]	Tong A W,Fulgham P,Jay C,et al.MicroRNA profile analysis of human prostate cancers[J].Cancer Gene Ther,2009,16(3):206-216.
[43]	Barron N,Keenan J,Gammell P,et al.Biochemical relapse following radical prostatectomy and miR-200a levels in prostate cancer[J].Prostate,2012,72(11):1193-1199.
[44]	Kristensen H,Thomsen A R,Haldrup C,et al.Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling[J].Oncotarget,2016,Apr 23.
[45]	Roberts M J,Chow C W,Schirra H J,et al.Diagnostic performance of expression of PCA3,Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer[J].Prostate,2015,75(5):539-549.